Document Type

Article

Publication Date

2-27-2020

Abstract

The National Center for Posttraumatic Stress Disorder (PTSD) reported approximately seven to eight people out of 100 will develop PTSD at some point in their lives and an estimated eight million adults will develop PTSD during a given year. It is also estimated between 55-60% of persons diagnosed with PTSD are diagnosed with a substance-use disorder (SUD). However, despite clinical guidelines that increasingly recommend the use of psychotherapies within the same treatment episode for clients with comorbid SUD/PTSD and client preferences for combined PTSD/SUD treatment, clinicians tend to overlook comorbid trauma and substance issues and/or are inclined to provide separate treatment for comorbid trauma and substance-related issues. This review is designed to provide a synopsis of the most effective, evidence-based psychotherapeutic treatments for comorbid PTSD/SUD, with emphasis on recent advancements in mindfulness approaches. The review also discusses ketamine infusion therapy (KIT), a newly developed psychopharmacological approach for treatment-resistant PTSD and comorbid SUD.

Comments

Copyright The Authors. This work is licensed under Creative Commons Attribution 4.0 License

Creative Commons License

Creative Commons Attribution 4.0 International License
This work is licensed under a Creative Commons Attribution 4.0 International License.

DOI

http://doi.org/10.33552/OAJAP.2020.03.000565

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.